FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

Conn. Gen. Stat. §20-627 defines a nonresident pharmacy as one outside Connecticut that ships, mails or delivers legend drugs or devices into the state under a prescription. It must register with the Department of Consumer Protection upon approval of the Commission of Pharmacy. Before registration it must submit its most recent home-state inspection report, which must include a USP <797> section if it delivers sterile compounded products. It must also keep its home license, report ownership changes within 10 days and discipline within 10 business days, provide a toll-free pharmacist line, and supply recall recipient lists within 24 hours. A nonresident pharmacy that dispenses non-patient-specific sterile products must file its home-state manufacturing license or registration and any FDA registration. Under §20-633b(b)(2), a nonresident pharmacy may not compound sterile products for Connecticut until a sterile-compounding addendum is approved, which requires written proof it passed a home-state inspection.

The statute does not require a Connecticut-licensed pharmacist-in-charge; it requires disclosure of pharmacists dispensing to Connecticut residents. §20-627 was last amended by P.A. 18-141.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

Regs. Conn. State Agencies §20-576-71(c) lets a non-sterile compounding pharmacy (defined as a pharmacy licensed under §20-594) provide non-patient-specific non-sterile compounded products to physicians, osteopaths, podiatrists, dentists and veterinarians to administer in their practice, limited to a 30-day supply. For sterile products, Conn. Gen. Stat. §20-633b(d)(1) says a sterile compounding pharmacy may only provide patient-specific sterile pharmaceuticals to patients, practitioners or facilities. Under §20-633b(d)(2), one that provides sterile products without a patient-specific prescription must also obtain a Department of Consumer Protection registration under §21a-70 and any required federal license or registration, and may keep no more than a 30-day on-site inventory. An older rule allowing a two-week sterile office supply (§20-576-66(c), 2011) predates these statutory limits. A nonresident pharmacy dispensing non-patient-specific sterile products must file its home-state manufacturing license and FDA registration (§20-627(b)(4)).

The non-sterile office-use rule applies by its terms to pharmacies licensed under §20-594 (in-state). Whether a registered nonresident pharmacy may ship non-sterile office-use stock into Connecticut is not expressly addressed. The regulation compilation is dated 2024-12-27, within the 2-year window. The 30-day non-sterile supply allowance is broader than FDA's patient-specific reading of 503A.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

Conn. Gen. Stat. §21a-70 requires wholesalers and manufacturers to hold a DCP certificate of registration, renewed annually. It defines 'manufacturer' to include anyone inside or outside Connecticut who compounds drugs for sale, and any sterile compounding pharmacy that dispenses sterile products without a prescription or patient-specific order. §21a-70(b) exempts from the certificate an out-of-state manufacturer that is registered with FDA and files a copy of that registration with the Commissioner, but not a sterile compounding pharmacy as defined in §20-633b. A 503B that is not a pharmacy therefore appears to need either a DCP certificate or an FDA-registration filing with DCP. A 503B that also operates as a pharmacy and ships non-patient-specific sterile products needs a §21a-70 registration plus nonresident pharmacy registration (§20-627(b)(4); §20-633b(d)(2)). The statutes do not use the term 'outsourcing facility'.

How DCP treats FDA 503B outsourcing-facility registration under the §21a-70(b) out-of-state FDA-registered manufacturer exemption was not confirmed; no DCP outsourcing-facility guidance was reviewed. Check with the Connecticut Department of Consumer Protection, Drug Control Division.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Connecticut is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

Conn. Gen. Stat. Sec. 21a-317 requires every practitioner who distributes, administers or dispenses, or proposes to distribute, prescribe, administer or dispense, any controlled substance in Connecticut to obtain a certificate of registration from the Commissioner of Consumer Protection and, if prescribing, to register with the state PDMP (CPMRS). 'Practitioner' expressly includes physicians, physician assistants, APRNs and nurse-midwives (Sec. 21a-316). The application fee is $20 and the registration is biennial (Sec. 21a-318); renewal is $40 biennially, and a separate fee is required for each place of business or professional practice where the practitioner stores, distributes or dispenses controlled substances (Sec. 21a-321). Since 2022, a practitioner who transports controlled substances to treat a patient at a location other than the registered address must notify DCP first and return unused drug to the registered address.

DCP's own practitioner-registration pages (portal.ct.gov/dcp) could not be reached in this session (DNS failure), so fees are from the statute, not the agency page. DEA registration requires state authority to handle controlled substances, so in practice the DCP registration comes first. Per-location: a separate fee is charged for each site where controlled substances are stored or dispensed.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Conn. Gen. Stat. 21a-254(j)(9) requires the prescribing practitioner or authorized agent to review the patient's PDMP record before prescribing greater than a 72-hour supply of any controlled substance. For continuous or prolonged treatment, the review must be repeated at least every 90 days (annually for Schedule V nonnarcotic drugs). If the system is down, a practitioner may prescribe and must review within 24 hours of regaining access. The section does not apply to samples dispensed by a physician or controlled substances dispensed to hospital inpatients. Administered by the Department of Consumer Protection, with discipline under 21a-322.

Frequency: before any Rx over a 72-hour supply, then at least every 90 days for ongoing treatment. Testosterone (C-III) is caught when prescribed for more than 72 hours. The duty is framed around prescribing; in-office administration is not expressly addressed. The CGA 'current' chapter page is revised to January 1, 2025 and refers readers to the 2026 Supplement (revised to Jan 1, 2026) for 2025-session changes, which was not checked. The DCP PMP page could not be reached (DNS failure).

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

Conn. Gen. Stat. 20-14c to 20-14f govern practitioner dispensing. Drugs must be personally dispensed by the prescribing practitioner (no delegation, except nurses in hospital emergency departments), recorded in the chart, packaged in child-resistant containers and labeled with patient, prescriber, date, directions and cautions. A practitioner who dispenses anything other than professional samples must notify the Commissioner of Consumer Protection and confirm the intent to continue every two years at renewal of the state controlled substance registration (Sec. 21a-317).

Answer is yes because only a notice (not a permit) is required; the state controlled substance registration is separately required for controlled substances.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

Telehealth providers must hold the appropriate Connecticut license; a temporary out-of-state registration for behavioral health ended June 30, 2025. Conn. Gen. Stat. 19a-906(c) says no telehealth provider may prescribe any Schedule I, II or III controlled substance through telehealth, except a non-opioid Schedule II or III drug prescribed consistent with the federal Ryan Haight Act to treat a psychiatric disability or substance use disorder. Testosterone therefore requires an in-person visit to prescribe. Non-controlled drugs such as GLP-1s, sildenafil and finasteride follow the ordinary standard of care. IMLC: member (IMLC map dated 3/15/2026).

CCHP quotes an older wording of 19a-906 (MAT or psychiatric exception); the official text revised to January 1, 2026 limits the exception to non-opioid Schedule II/III drugs for psychiatric disability or SUD. Check for 2026 session changes.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The Connecticut Board of Examiners for Nursing (Department of Public Health)'s website was checked on 2026-09-23 for a position statement, advisory opinion or FAQ on cosmetic injectables (neuromodulators, fillers) and none was found (the site blocked automated access). RN practice therefore falls under the state's general nurse practice act, which was not reviewed for this entry.

Board site returned HTTP 403 or did not resolve for automated requests on 2026-09-23; URL taken from the MedGrid agency directory. A Connecticut medical spa statute was searched for in the General Statutes chapters on DPH and medicine (cga.ct.gov) but not found.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The Connecticut Board of Examiners for Nursing (Department of Public Health)'s website was checked on 2026-09-23 for guidance on IV hydration clinics (prior exams, standing orders, mobile services) and none was found (the site blocked automated access).

Board site returned HTTP 403 or did not resolve for automated requests on 2026-09-23; URL taken from the MedGrid agency directory.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide rates Connecticut 'Moderate', citing Conn. Gen. Stat. §33-182bb and Public Act 09-212; MedPath Compliance (reviewed 2026-06-20) lists it as 'Yes' and reports SB 196 (signed 2026-05-27) limiting private-equity/REIT hospital deals and banning sale-leasebacks.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

No Connecticut statute, rule or board policy on delegation of cosmetic laser/IPL procedures or a laser-operator credential was located on 2026-09-23 (the board site blocked automated access).

Board site returned HTTP 403 or did not resolve for automated requests on 2026-09-23; URL taken from the MedGrid agency directory.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Connecticut was not among them, but this research did not confirm its statutes. Connecticut's CLIA state agency is Connecticut Dept. of Public Health, Facility Licensing & Investigations (DPH.FLISLab@ct.gov, 860-509-7400); it can confirm whether any state license or permit applies, including to out-of-state labs.

Connecticut may run its own in-state lab licensing program; this could not be confirmed from a primary source in this pass, so check with the agency before relying on CLIA alone.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Connecticut's rule. Connecticut's lab regulator (CLIA state agency) is Connecticut Dept. of Public Health, Facility Licensing & Investigations (DPH.FLISLab@ct.gov, 860-509-7400). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Connecticut is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Public Act 24-59 (Substitute SB 292, 2024; C.G.S. §22a-903c): starting July 1, 2026, manufacturers of cosmetics containing intentionally added PFAS must give prior written notice to the Department of Energy and Environmental Protection (DEEP) and label the products. From Jan 1, 2028, manufacturing or selling cosmetics with intentionally added PFAS is prohibited. Unavoidable trace quantities are excepted.

The Connecticut statutes website could not be reached (certificate error), so the dates are from two consistent 2026 law-firm and compliance compilations. Federal MoCRA and FDA cosmetic and OTC sunscreen rules apply in every state.